What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options

Postgraduate Medicine

Volumn 105, Issue 1, 1999, Pages 109-118

  Shadlen, Marie Florence ^a   Larson, Eric B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; DICHLORVOS; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; ESTROGEN; GERIMAL; GINKGO BILOBA EXTRACT; INDOMETACIN; METRIFONATE; RIVASTIGMINE; SELEGILINE; SUXAMETHONIUM; TACRINE; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BLEEDING; BREAST DISEASE; CHOLELITHIASIS; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DOSE RESPONSE; DRUG COST; DYSKINESIA; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; THROMBOEMBOLISM; VERTIGO;

EID: 0032947533     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1999.01.500     Document Type: Article

References (25)

1. Alzheimer's disease: symptomatic drugs under development. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. London: M. Dunitz, 1996:239-59
2. Knopman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology 1994;44(12):2315-21
3. Standish TI, Molloy DW, Bedard M, et al. Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). J Am Geriatr Soc 1996;44(6):712-6
4. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98
5. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412-4
6. Schwartz GE. Development and validation of the geriatric evaluation by relatives rating instrument (GERRI). Psychol Rep 1983;53(2):479-88
7. Knapp MJ, Knopman DS, Solomon PR, et al, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271(13):985-91
8. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271(13):992-8
9. Rogers SL, Doody RS, Mohs RC, et al, for the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158(9):1021-31
10. Rogers SL, Farlow MR, Doody RS, et al, for the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50(1):136-45
11. Ham RJ. Clinical efficacy of donepezil hydrochloride in patients with Alzheimer's disease: case studies. Adv Ther 1997; 14(5):223-33
12. Unni LK, Womack C, Hannant ME, et al. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Methods Find Exp Clin Pharmacol 1994;16(4):285-9
13. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50(5):1214-21
14. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998;38(3):236-45
15. Fulton B, Benfield P. Galanthamine. Drugs Aging 1996;9(1):60-5; discussion 66-7
16. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58(15):1201-7
17. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54(4):465-73
18. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43(8):1609-11
19. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997;48(5 Suppl 7):S36-41
20. Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996;46(6):1580-4
21. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336(17):1216-22
22. Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29(2):47-56
23. Le Bars PL, Katz MM, Berman N, et al, for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia, JAMA 1997; 278(16);1327-32
24. Lovestone S, Graham N, Howard R. Guidelines on drug treatments for Alzheimer's disease. Lancet 1997;350(9073):232-3
25. Kelly CA, Harvey RJ, Cayton H. Drug treatments for Alzheimer's disease. (Editorial) BMJ 1997;314(7082):693-4